Alnylam launches “alnylam p5x25” strategy for planned transition to a top five biotech in market capitalization over next five years

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced its new 5-year strategy “alnylam p5x25” focused on the company's planned transition to a top-5 biotech (measured by market capitalization) in the next 5 years through: sustainable innovation yielding transformative medicines for rare and common diseases for patients around the world and delivery of exceptional financial performance. alnylam p5x25 extends the co
ALNY Ratings Summary
ALNY Quant Ranking